“America’s private health insurance system is far more costly with far poorer results than the public option programs in Europe.” So writes Nobel-prize-winning economist Joseph Stiglitz in his new book. His solution to fix healthcare: “people power.” His conclusion lines up with Fixing U.S. Healthcare blog. He agrees that the healthcare system needs more than the … Continue reading Nobel Economist: What It Will Take to Fix U.S. Healthcare
Business school courses on managing organizational change often begin with how to deal with resistance to change. They teach business leaders first to distinguish between true resistance – recognition by front-line staff of real obstacles – and pseudo-resistance, the natural human tendency to fear anything unfamiliar. We are seeing the emergence of true resistance this … Continue reading Healthcare Reform: New Resistance, New Traction
Once again, healthcare reform is at the forefront of the U.S. political debate. CNN allotted healthcare the lead-off spot and 22 minutes on both nights of its Democratic Presidential Debates this week, more than for any other issue. Senator Cory Booker (D-NJ) perhaps best captured the key challenge -- unsustainable costs: In the United States … Continue reading Candidates Debate Healthcare Reform
“We are at the mercy of the private insurance and pharmaceutical companies, whose greed dictates the cost of healthcare,” railed Democrat Presidential candidate Senator Bernie Sanders in a recent campaign blurb. Are insurance and drug companies really the ones to blame for our healthcare problem – unsustainable costs and millions without access? If so, are … Continue reading Healthcare Reform: Are Insurance Companies and Drug Companies the Culprits?
On the stump, many of the candidates are railing against skyrocketing drug costs. They promise at campaign rallies at the top of their lungs to “Bring down the cost of drugs.” This blog, however, claims that it’s not only about costly drugs. It’s the whole system that is rigged and has high costs baked into … Continue reading It’s Not Just About Costly Drugs – It’s Testing, Too